Table 2.

Characteristics of response and progression in all patients

	N (%)
Primary resistance
Yes	38 (42%)
No	52 (58%)
New or existing lesion at progression
New	31 (34%)
Existing	29 (32%)
Additional treatment post ICI (n = 53, 58%)	53 (58%)
VEGFR2 TKI containing therapy (n = 39, 74%)	39 (74%)
Cabozantinib	17 (32%)
Axitinib	9 (17%)
VEGFR2 TKI + ICI	6 (11%)
Lenvatinib + everolimus	2 (5%)
Sunitinib	2 (4%)
Lenvatinib	1 (2%)
Pazopanib	1 (2%)
Sorafenib	1 (2%)
Clinical trial, other	8 (15%)
Other (radiation only, hospice)	3 (6%)
Everolimus	2 (4%)
Nivolumab + ipilimumab	1 (2%)
Immune-related adverse events (irAE)
No	66 (73%)
Type of irAEs
Colitis	8 (33%)
Pneumonitis	5 (21%)
Hepatitis	3 (13%)
Dermatitis	3 (12%)
irAEs causing treatment discontinuation
Yes	13 (54%)